FATE's near-term price action will be driven by enrollment updates for RECLAIM-LN and initial dosing data from the FT839 COMPLETE trial, not quarterly financials. Monitor for patient enrollment acceleration and any early efficacy signals from the FT839 Phase 1/2 basket study, which could be a major catalyst in H2 2026.
Drugs in focus
FATE drug pipeline →FT819
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $2.52entry
- T+1 · 3mo ago +1.98%α +2.18% · $2.57
- T+5 · 3mo ago −3.17%α −1.21% · $2.44
- T+20 · 2mo ago −8.33%α −6.59% · $2.31
- T+60 · 11d ago −27.18%α −21.71% · $1.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate of -$0.26. The pre-revenue biotech's key catalysts are clinical milestones: first patient dosed in the potentially registrational RECLAIM-LN trial for FT819 in lupus nephritis, and FDA clearance of the FT839 IND for a Phase 1/2 autoimmune basket trial. Cash burn of $21M in the quarter leaves a runway into 2028, but with no revenue growth or path to profitability, the stock's direction hinges entirely on clinical execution and regulatory updates rather than financial performance.
Key Financial Metrics
Key Facts
- First patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis; patient treated as outpatient with same-day discharge.
- FDA cleared IND for FT839, a next-generation dual CD19/CD38 CAR T-cell product candidate, advancing into a Phase 1/2 basket trial in autoimmune disease.
- Cash, cash equivalents, and investments were $153.8M as of June 30, 2026, a quarterly decrease of $21M; cash runway expected into 2028.
- Net loss was $30.2M ($0.25 per share) for Q2 2026, compared to $34.1M ($0.29 per share) in Q2 2025.
- Revenue was $2.1M for Q2 2026, derived from the Ono Pharmaceutical collaboration, compared to $1.9M in Q2 2025.
- Preliminary FT819 data in systemic sclerosis (SSc) showed rCRISS25 or greater responses and improvement in mRSS in all four treated patients.
Financial Impact
Quarterly net loss of $30.2M; cash burn of $21M; no revenue growth trajectory. Financials are secondary to clinical catalysts for this pre-revenue biotech.
Risk Factors
- Clinical trial failure or slower-than-expected enrollment in RECLAIM-LN or FT839 trials.
- Cash runway into 2028 depends on expense discipline; any unexpected cost overruns could necessitate dilutive financing.
- Competitive landscape for off-the-shelf CAR T-cell therapies in autoimmune diseases is rapidly evolving.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347984 |
| Document: fate-20260813.htm | 0001193125-26-347984 |
| Document: 0001193125-26-347984-index-headers.html | 0001193125-26-347984 |
| Document: 0001193125-26-347984-index.html | 0001193125-26-347984 |
| Document: 0001193125-26-347984.txt | 0001193125-26-347984 |
| 8-K Data (Synthetic) | 0001193125-26-347984 |
Track record
21 reports on FATE
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers